Research · Sep 3, 2026
[MDLN] Medline Thesis 2026: Post-IPO Hospital Supply Distribution Drives Scale Economics
Medline Industries Inc. (NYSE: MDLN) FY2025 revenue ~$25-27B (+5-9%) with adj. EPS ~$2.65-3.10 reflecting continued ~190,000+ aggregate medical-surgical product portfolio plus selected ~50%+ US hospital + ~75%+ US nursing home + selected various US healthcare facility distribution coverage plus selected post-October 2025 ~$5B aggregate NYSE IPO (~50M shares at ~$45-55/share initial pricing range) supporting selected various capital structure optimization + selected various investment grade credit upgrade pathway under continued co-Chairman + co-CEO Charlie Mills + co-Chairman Jim Mills + co-CEO Andy Mills (third generation Mills family co-leadership). Largest US privately-held medical-surgical product distributor + manufacturer with operations across medical-surgical product manufacturing + distribution + selected various healthcare services in 100+ countries. Founded 1910 as A.L. Mills + Company in Chicago Illinois by A.L. Mills (~115-year heritage; selected one of US oldest continuing healthcare distributors); selected post-1966 Medline Industries rebrand; selected post-1980s national distribution expansion; selected post-1990s ~190,000+ medical-surgical product portfolio expansion; selected post-October 2021 ~$34B aggregate Medline take-private buyout by Blackstone + Carlyle + Hellman & Friedman + GIC consortium; selected post-October 2025 ~$5B aggregate NYSE IPO (selected one of largest US healthcare IPOs FY2025). Headquartered in Northfield Illinois; ~43,000+ employees globally with ~$25-27B revenue. Three primary reporting segments: Medical-Surgical Products Manufacturing + Distribution (~70% revenue ~$17.5-19B — ~190,000+ aggregate medical-surgical product portfolio; ~50%+ US hospital + ~75%+ US nursing home distribution coverage), International (~20% revenue ~$5-5.5B — selected various international distribution + selected various manufacturing across Canada + Mexico + Europe + Asia), Other (~10% revenue ~$2.5-3B — selected various services + selected continued various). Hospital supply distribution leadership: ~50%+ US hospital + ~75%+ US nursing home distribution coverage; ~190,000+ aggregate medical-surgical product portfolio; ~50+ aggregate US distribution centers; selected continued Medline digital health + selected various. Post-October 2025 IPO + capital structure: ~$5B aggregate IPO; ~$50B+ post-money implied valuation; ~$3-4B aggregate net proceeds debt paydown; selected continued Mills family ~30%+ retained ownership + Blackstone + Carlyle + Hellman & Friedman + GIC consortium co-control structure. International expansion: ~$5-5.5B aggregate FY2025 revenue including Canada + Mexico + Europe + Asia + selected various. Co-Chairman + Co-CEO Charlie Mills + Co-Chairman Jim Mills + Co-CEO Andy Mills (third generation Mills family co-leadership; ~30+-year aggregate company career); CFO Joe Lyons. Capital structure: ~$15-18B aggregate cumulative debt FY2025 (post-2021 leveraged buyback continuation); selected modest dividend (selected post-IPO initiation potential); no buybacks (capital priority on growth + debt paydown); selected post-2025 IPO ~$3-4B aggregate net proceeds debt paydown; investment-grade B1/BB- credit rating (post-2025 IPO upgrade pathway). FY2026 thesis: post-October 2025 IPO operational execution + ~$3-4B aggregate net proceeds debt paydown + hospital supply distribution leadership + International expansion + selected potential post-2026 dividend initiation. Risks: hospital + nursing home capital cycle, post-IPO trading performance, Mills family + private equity sponsor governance, Cardinal Health + McKesson + Henry Schein competitive intensity, ~$15-18B aggregate cumulative debt structure.